http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014190849-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f312cc7676e939dee48fb4fdfe921ce8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 |
| filingDate | 2014-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96dd2ba9c2819add7d0316a98d4541ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2611d6238cdf2068ac1f32dfa522e264 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ddc129ee226a84b251613825047558d |
| publicationDate | 2014-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2014190849-A1 |
| titleOfInvention | Doxorubicin prodrug, method of preparing same, and injectable combination |
| abstract | A doxorubicin prodrug, a method of preparing same, and an injectable combination. The Doxorubicin prodrug is made of MPEG and DOX being connected through a hydrazone bond, of which the preparing method is simple and has low requirements for reaction conditions, a high yield rate, and production cost easy to control. The prodrug has low immune responsiveness, can effectively increase the water solubility of doxorubicin, has long in vivo elimination time and can effectively prolong the effect time of the drug, and has pH sensitivity and can release in situ doxorubicin in an acidic environment and form PEG at the same time. The doxorubicin prodrug combination is soluble in a near-neutral aqueous solution to form a water solution having stable properties. When the pH is changed to be acidic, supermolecule water gel may be formed within several minutes to achieve long-term in-situ release of doxorubicin, thereby effectively avoiding dispersion of doxorubicin to affect the functions of normal cells and reducing side effects of the drug. |
| priorityDate | 2013-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.